Psychedelic medicine is the solution to the Mental Health Crisis. Psychedelic drugs are a huge commercial opportunity. Big Business moves in.

We take a closer look at each of the three psychedelics ETFs and analyze the investment objectives that each ETF addresses.

Activists in Italy say they’ve gathered enough signatures to qualify a ballot measure that would decriminalize personal cultivation and use of not only marijuana but also psilocybin mushrooms and certain other psychoactive plants for personal use.

Clinical research is rapidly advancing in using psychedelic drugs to treat opioid addiction. However, psychedelics can also reduce opioid-related deaths as a SUBSTITUTE for opioids.

New Hampshire lawmakers have a new strategy to legalize marijuana in the state that involves putting a proposed constitutional amendment on the ballot for voters to decide on in 2022.

South Dakota lawmakers on Monday approved most of the state Department of Health rules for the state’s voter-approved medical cannabis program but rejected some proposals including limiting the amount of high-potency cannabis patients can possess, requirements that medical practitioners could write recommendations for patients that want to grow more than the three plants allowed under the law, and a defined list of qualifying conditions, the Associated Press reports.

AdvisorShares’ new psychedelics ETF commences trading today on the NYSE Arca Exchange (symbol “PSIL”) with a focus on small-cap psychedelic stocks.

California activists are now cleared to begin collecting signatures for an initiative to legalize psilocybin mushrooms in the state.

The Missouri Department of Health and Senior Services said Thursday that it had initiated the second required transfer of revenue from the state’s new medical marijuana program to the Missouri Veterans Commission.